普莱柯拟控股中普生物 加码动物疫苗业务布局

Core Viewpoint - The company, Pulaike (普莱柯), plans to acquire a 4.04% stake in Zhongpu Biopharmaceutical Co., Ltd. (中普生物) from CITIC Agricultural Technology Co., Ltd. (中信农业), which will enhance its control over the veterinary vaccine market, particularly in foot-and-mouth disease vaccines, aligning with its long-term development strategy [1][2]. Group 1 - The acquisition will allow Pulaike to gain control over Zhongpu Biopharmaceutical, improving its product matrix and business synergy in the livestock vaccine sector [1][2]. - Zhongpu Biopharmaceutical was established in June 2018 by Pulaike, China Animal Husbandry Industry Co., Ltd. (中牧股份), and CITIC Agricultural, with current ownership stakes of 46.97%, 48.99%, and 4.04% respectively [1]. - The stake being acquired is valued at 17.5143 million yuan (approximately 2.5 million USD) [1]. Group 2 - Zhongpu Biopharmaceutical reported net losses of 26.2074 million yuan (approximately 3.7 million USD) for 2024 and 18.237 million yuan (approximately 2.6 million USD) for the first half of the year [3]. - Pulaike aims to improve Zhongpu's operational efficiency and sustainability through this acquisition, which is in line with its strategic planning and shareholder interests [3]. - The acquisition may require Pulaike to invest additional resources to optimize Zhongpu's business model, which could have a short-term impact on its profits [3].